4D Molecular Therapeutics' (FDMT) "Buy" Rating Reiterated at Chardan Capital

Key Points

• 4D Molecular Therapeutics received a reiterated "buy" rating from Chardan Capital, with a price target of $25.00, indicating a potential upside of 352.08% from its previous close.
• Goldman Sachs and Barclays both lowered their price targets for the stock, while Weiss Ratings issued a "sell (d-)" rating, reflecting mixed analyst sentiment.
• 4D Molecular Therapeutics reported a quarterly loss of ($0.98) EPS, missing analyst estimates and facing negative returns on equity and margins.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $25.00 price objective on the stock. Chardan Capital's target price points to a potential upside of 352.08% from the company's previous close.

Other equities research analysts have also issued research reports about the company. The Goldman Sachs Group lowered their price objective on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research report on Tuesday, July 29th. Finally, Barclays reduced their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, 4D Molecular Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $29.56.

4D Molecular Therapeutics Trading Down 1.8%

NASDAQ FDMT opened at $5.53 on Tuesday. The stock has a market cap of $256.20 million, a P/E ratio of -1.74 and a beta of 2.83. The company's fifty day simple moving average is $4.46 and its 200-day simple moving average is $4.08. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $17.41.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.29). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. On average, research analysts expect that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors have recently modified their holdings of the business. Decheng Capital LLC boosted its stake in 4D Molecular Therapeutics by 0.5% in the fourth quarter. Decheng Capital LLC now owns 400,000 shares of the company's stock valued at $2,228,000 after acquiring an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of 4D Molecular Therapeutics by 7.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock worth $247,000 after purchasing an additional 2,925 shares during the last quarter. ProShare Advisors LLC lifted its holdings in shares of 4D Molecular Therapeutics by 30.1% in the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company's stock worth $91,000 after purchasing an additional 3,783 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in 4D Molecular Therapeutics by 35.6% during the 2nd quarter. Dynamic Technology Lab Private Ltd now owns 16,369 shares of the company's stock valued at $61,000 after purchasing an additional 4,295 shares during the period. Finally, American Century Companies Inc. grew its stake in 4D Molecular Therapeutics by 12.9% during the 4th quarter. American Century Companies Inc. now owns 38,785 shares of the company's stock worth $216,000 after buying an additional 4,429 shares during the last quarter. Institutional investors own 99.27% of the company's stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.